ATE500251T1 - Benzimidazole und ihre verwendung zur behandlung von diabetes - Google Patents

Benzimidazole und ihre verwendung zur behandlung von diabetes

Info

Publication number: ATE500251T1
Authority: AT; Austria
Prior art keywords: phenyl; benzimidazoles; diabetes; treatment; dgat1
Prior art date: 2006-06-08

Application number

AT07733082T

Other languages

English (en)

Inventor

Alan Martin Birch

Roger John Butlin

Alleyn Plowright

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-08

Filing date

2007-06-06

Publication date

2011-03-15

2007-06-06 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE500251T1 publication Critical patent/ATE500251T1/de

Links

150000001556 benzimidazoles Chemical class 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 abstract 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 abstract 1
102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 abstract 1
102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 abstract 1
101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 abstract 1
229940100228 acetyl coenzyme a Drugs 0.000 abstract 1
150000001602 bicycloalkyls Chemical group 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Virology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
AIDS & HIV (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)

AT07733082T 2006-06-08 2007-06-06 Benzimidazole und ihre verwendung zur behandlung von diabetes ATE500251T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81189506P	2006-06-08	2006-06-08
PCT/GB2007/002070 WO2007141517A1 (en)	2006-06-08	2007-06-06	Benzimidazoles and their use for the treatemnt of diabetes

Publications (1)

Publication Number	Publication Date
ATE500251T1 true ATE500251T1 (de)	2011-03-15

Family

ID=38510308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07733082T ATE500251T1 (de)	2006-06-08	2007-06-06	Benzimidazole und ihre verwendung zur behandlung von diabetes

Country Status (16)

Country	Link
US (1)	US20090197926A1 (de)
EP (1)	EP2035417B1 (de)
JP (1)	JP2009539818A (de)
KR (1)	KR20090016629A (de)
CN (1)	CN101460492A (de)
AT (1)	ATE500251T1 (de)
AU (1)	AU2007255180B2 (de)
CA (1)	CA2655225A1 (de)
DE (1)	DE602007012875D1 (de)
ES (1)	ES2359653T3 (de)
IL (1)	IL195912A0 (de)
MX (1)	MX2008015725A (de)
NO (1)	NO20085216L (de)
NZ (1)	NZ573576A (de)
WO (1)	WO2007141517A1 (de)
ZA (1)	ZA200810643B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0519058A2 (pt)	2004-12-14	2008-12-23	Astrazeneca Ab	composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2007071966A1 (en) *	2005-12-22	2007-06-28	Astrazeneca Ab	Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
EP2418202B1 (de)	2006-03-31	2014-01-29	Novartis AG	(4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivate als DGAT- Inhibitoren
MX2008015228A (es)	2006-05-30	2008-12-12	Astrazeneca Ab	Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
CN101460470B (zh) *	2006-05-30	2011-05-18	阿斯利康(瑞典)有限公司	作为dgat1抑制剂的1,3,4-二唑衍生物
NZ580660A (en)	2007-04-30	2012-02-24	Abbott Lab	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
AR066169A1 (es)	2007-09-28	2009-07-29	Novartis Ag	Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
NZ586104A (en)	2007-12-20	2012-02-24	Astrazeneca Ab	Carbamoyl compounds as dgat1 inhibitors 190
WO2009112445A1 (en) *	2008-03-10	2009-09-17	Novartis Ag	Method of increasing cellular phosphatidyl choline by dgat1 inhibition
TW201010700A (en)	2008-08-25	2010-03-16	Piramal Lifesciences Ltd	Diacylglycerol acyltransferase inhibitors
KR20110102910A (ko) *	2008-12-19	2011-09-19	아스트라제네카 아베	1,3,4-옥사디아졸 유도체 및 당뇨병의 치료를 위한 이의 용도
EP2805951B1 (de)	2009-03-20	2018-03-14	Metabasis Therapeutics, Inc.	Inhibitoren von Diacylglycerin-O-acyltransferase 1 (DGAT-1) und Verwendungen davon
EP2423182A4 (de)	2009-04-21	2012-11-07	Astellas Pharma Inc	Diacylethylendiaminverbindung
TW201103895A (en) *	2009-06-19	2011-02-01	Astrazeneca Ab	Chemical compounds
TW201236685A (en) *	2010-11-11	2012-09-16	Daiichi Sankyo Co Ltd	New pyrazole amide derivatives
WO2023167545A1 (ko) *	2022-03-04	2023-09-07	한국화학연구원	보호기가 도입된 폴리벤즈이미다졸, 이를 이용한 막의 제조방법 및 이의 용도
KR102900338B1 (ko) *	2022-03-04	2025-12-15	한국화학연구원	보호기가 도입된 폴리벤즈이미다졸, 이를 이용한 막의 제조방법 및 이의 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4017503A (en) *	1975-06-12	1977-04-12	Merck & Co., Inc.	Antifungal 1-substituted benzimidazoles
US4983731A (en) *	1989-03-17	1991-01-08	Nebraska Department Of Economic Development	Separation and purification of sugar esters
US5491172A (en) *	1993-05-14	1996-02-13	Warner-Lambert Company	N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US20030167483A1 (en) *	1998-06-24	2003-09-04	Farese Robert V.	Diacylglycerol O-acyltransferase
WO2000058491A1 (en) *	1999-03-25	2000-10-05	The Kitasato Institute	Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same
ATE316980T1 (de) *	1999-07-21	2006-02-15	Univ Southern California	Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
GB0021670D0 (en) *	2000-09-04	2000-10-18	Astrazeneca Ab	Chemical compounds
CA2369967A1 (en) *	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methods of treating nuclear factor-kappa b mediated diseases and disorders
AU2002333456B2 (en) *	2001-08-31	2008-07-17	Sanofi-Aventis Deutschland Gmbh	Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
FR2840301B1 (fr) *	2002-05-29	2007-03-23	Sanofi Synthelabo	Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
MXPA05000053A (es) *	2002-07-12	2005-04-08	Aventis Pharma Gmbh	Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos.
JP4164645B2 (ja)	2002-08-09	2008-10-15	株式会社大塚製薬工場	Ｄｇａｔ阻害剤
RU2342388C2 (ru) *	2002-11-22	2008-12-27	Джапан Тобакко Инк.	Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
AR044152A1 (es) *	2003-05-09	2005-08-24	Bayer Corp	Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en)	2003-08-07	2005-02-17	Japan Tobacco Inc.	Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) *	2003-10-29	2003-12-03	Astrazeneca Ab	Method of use
WO2006004200A1 (ja) *	2004-07-02	2006-01-12	Sankyo Company, Limited	ウレア誘導体
JP2006083158A (ja) *	2004-08-16	2006-03-30	Sankyo Co Ltd	置換されたウレア化合物
BRPI0519058A2 (pt) *	2004-12-14	2008-12-23	Astrazeneca Ab	composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2006082952A1 (ja) *	2005-02-01	2006-08-10	Takeda Pharmaceutical Company Limited	アミド化合物
AU2006258917A1 (en) *	2005-06-11	2006-12-21	Astrazeneca Ab	Oxadiazole derivatives as DGAT inhibitors
KR20080063865A (ko) *	2005-11-28	2008-07-07	에프. 호프만-라 로슈 아게	다이아실글리세롤 아실전이효소(ｄｇａｔ)의 저해제
WO2007071966A1 (en) *	2005-12-22	2007-06-28	Astrazeneca Ab	Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
CN101460470B (zh) *	2006-05-30	2011-05-18	阿斯利康(瑞典)有限公司	作为dgat1抑制剂的1,3,4-二唑衍生物
MX2008015228A (es) *	2006-05-30	2008-12-12	Astrazeneca Ab	Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
WO2007141502A1 (en) *	2006-06-06	2007-12-13	Astrazeneca Ab	Chemical compounds
GB0611506D0 (en) *	2006-06-10	2006-07-19	Astrazeneca Ab	Chemical compounds
GB0611507D0 (en) *	2006-06-10	2006-07-19	Astrazeneca Ab	Chemical compounds
US7569590B2 (en) *	2006-09-19	2009-08-04	Bristol-Myers Squibb Company	Use of thianecarboxamides as dgat inhibitors
NZ586104A (en) *	2007-12-20	2012-02-24	Astrazeneca Ab	Carbamoyl compounds as dgat1 inhibitors 190
KR20110102910A (ko) *	2008-12-19	2011-09-19	아스트라제네카 아베	1,3,4-옥사디아졸 유도체 및 당뇨병의 치료를 위한 이의 용도
TW201103895A (en) *	2009-06-19	2011-02-01	Astrazeneca Ab	Chemical compounds

2007
- 2007-06-06 WO PCT/GB2007/002070 patent/WO2007141517A1/en not_active Ceased
- 2007-06-06 US US12/303,512 patent/US20090197926A1/en not_active Abandoned
- 2007-06-06 NZ NZ573576A patent/NZ573576A/en not_active IP Right Cessation
- 2007-06-06 KR KR1020097000116A patent/KR20090016629A/ko not_active Withdrawn
- 2007-06-06 CA CA002655225A patent/CA2655225A1/en not_active Abandoned
- 2007-06-06 AU AU2007255180A patent/AU2007255180B2/en not_active Ceased
- 2007-06-06 CN CNA2007800210582A patent/CN101460492A/zh active Pending
- 2007-06-06 AT AT07733082T patent/ATE500251T1/de not_active IP Right Cessation
- 2007-06-06 ES ES07733082T patent/ES2359653T3/es active Active
- 2007-06-06 JP JP2009513759A patent/JP2009539818A/ja active Pending
- 2007-06-06 EP EP07733082A patent/EP2035417B1/de active Active
- 2007-06-06 DE DE602007012875T patent/DE602007012875D1/de active Active
- 2007-06-06 MX MX2008015725A patent/MX2008015725A/es not_active Application Discontinuation
2008
- 2008-12-14 IL IL195912A patent/IL195912A0/en unknown
- 2008-12-15 NO NO20085216A patent/NO20085216L/no not_active Application Discontinuation
- 2008-12-17 ZA ZA200810643A patent/ZA200810643B/xx unknown

Also Published As

Publication number	Publication date
MX2008015725A (es)	2009-02-13
WO2007141517A1 (en)	2007-12-13
AU2007255180A1 (en)	2007-12-13
US20090197926A1 (en)	2009-08-06
DE602007012875D1 (de)	2011-04-14
CA2655225A1 (en)	2007-12-13
NO20085216L (no)	2009-01-06
ZA200810643B (en)	2010-05-26
KR20090016629A (ko)	2009-02-16
AU2007255180B2 (en)	2011-02-03
HK1129099A1 (en)	2009-11-20
EP2035417B1 (de)	2011-03-02
NZ573576A (en)	2011-01-28
ES2359653T3 (es)	2011-05-25
EP2035417A1 (de)	2009-03-18
IL195912A0 (en)	2011-08-01
JP2009539818A (ja)	2009-11-19
CN101460492A (zh)	2009-06-17

Legal Events

Date	Code	Title	Description
2011-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE500251T1 (de)	2011-03-15	Benzimidazole und ihre verwendung zur behandlung von diabetes
ATE492541T1 (de)	2011-01-15	Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
MX2008012404A (es)	2008-10-09	Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
BRPI0707491B8 (pt)	2021-05-25	compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
MX2009012885A (es)	2009-12-10	Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
PE20081345A1 (es)	2008-10-24	Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
EA200701176A1 (ru)	2008-02-28	Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
MXPA05008619A (es)	2005-11-04	Derivados novedosos de 2-piridincarboxamida.
PE20110368A1 (es)	2011-06-13	Moduladores de mif
PE20130155A1 (es)	2013-02-21	Derivados de ariletinilo
CO6460743A2 (es)	2012-06-15	Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica
UA96947C2 (ru)	2011-12-26	Производные циннамоил-пиперазина и их применение как антагонистов par-1
ATE473221T1 (de)	2010-07-15	1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus
NZ592314A (en)	2013-02-22	Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
WO2008096769A1 (ja)	2008-08-14	置換されたセルコスポラミド誘導体を含有する医薬
TW200716531A (en)	2007-05-01	Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
GEP20135959B (en)	2013-11-11	Aryl piperazine and their usage as alpha2c antagonists
PE20141168A1 (es)	2014-09-22	Derivados de pirazolidin-3-ona
ATE486058T1 (de)	2010-11-15	Prolinamidderivate als nk3-antagonisten
UY29486A1 (es)	2006-11-30	Compuestos utiles en terapia
UY32632A (es)	2010-12-31	Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica.
MY183288A (en)	2021-02-18	Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these
SG154418A1 (en)	2009-08-28	Granular composition and production thereof
PE20081893A1 (es)	2009-02-15	Subtipo de amidas selectivas de diazabicicloalcanos
UA91646C2 (ru)	2010-08-10	Соединения индола, способ их получения и фармацевтическая композиция (варианты), которая их содержит